ScripFive biopharmaceutical companies were expected to go public in the US during the week of 17-21 June, but only four launched initial public offerings and one firm – the one with the most advanced drug
ScripThere is little doubt that Vertex Pharmaceuticals Inc. ’s cystic fibrosis transmembrane conductance regulator (CFTR) modulators Orkambi (lumacaftor/ivacaftor) and Kalydeco (ivacaftor) have change
ScripThe obesity market has not generated any blockbuster success stories for the biopharmaceutical industry, but Vivus Inc. still sells the prescription weight loss drug Qsymia (phentermine and topira
ScripVenture capital investment is limited for biopharma startups in Israel, with only a few specialized funds active in the market and tough competition for money between biopharma, medtech and digital he